Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 475

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

Evolution of drug delivery systems: From 1950 to 2020 and beyond

Open access
Park, Haesun, Otte, Andrew, Park, Kinam · 2022 · Journal of Controlled Release

Abstract

Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-release capsule technology, which can deliver a drug for 12 hours after oral administration through an initial immediate dose followed by the remaining released gradually. Until the 1980s, oral and transdermal formulations providing therapeutic durations up to 24 hours for small molecules dominated the drug delivery field and the market. The introduction of Lupron Depot® in 1989 opened the door for long-acting injectables and implantables, extending the drug delivery duration from days to months and occasionally years. Notably, the new technologies allowed long-term delivery of peptide and protein drugs, although limited to parenteral administration. The introduction of the first PEGylated protein, Adagen®, in 1990 marked the new era of PEGylation, resulting in Doxil® (doxorubicin in PEGylated liposome) in 1995, Movantik (PEGylated naloxone - naloxegol) in 2014, and Onpattro® (Patisiran - siRNA in PEGylated lipid nanoparticle) in 2018. Drug-polymer complexes were introduced, e.g., InFed® (iron-dextran complex injection) in 1974 and Abraxane® (paclitaxel-albumin complex) in 2005. In 2000, both Mylotarg™ (antibody-drug conjugate – gemtuzumab ozogamicin) and Rapamune® (sirolimus nanocrystal formulation) were introduced. The year 2000 also marked the launching of the National Nanotechnology Initiative by the U.S. government, which was soon followed by the rest of the world. Extensive work on nanomedicine, particularly formulations designed to escape from endosomes after being taken by tumor cells, along with PEGylation technology, ultimately resulted in the timely development of lipid nanoparticle formulations for COVID-19 vaccine delivery in 2020. While the advances in drug delivery technologies for the last seven decades are breathtaking, they are only the tip of an iceberg of technologies that have yet to be utilized in an approved formulation or even to be discovered. As life expectancy continues to increase, more people require long-term care for various diseases. Filling the current and future unmet needs requires innovative drug delivery technologies to overcome age-old familiar hurdles, e.g., improving water-solubility of poorly soluble drugs, overcoming biological barriers, and developing more efficient long-acting depot formulations. The lessons learned from the past are essential assets for developing future drug delivery technologies implemented into products. As the development of COVID-19 vaccines demonstrated, meeting the unforeseen crisis of the uncertain future requires continuous cumulation of failures, knowledge, and technologies. Conscious efforts of supporting diversified research topics in the drug delivery field are urgently needed more than ever.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2021.12.030

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 121 references

Research works printed but not linked: 12

  1. Ullyot, 2000, The metamorpohsis of Smith-Kline & French Laboratories to Smith Kline Beecham: 1925-1998, Bull. Hist. Chem., 25, 16, 10.70359/bhc2000v025p016 · doi:10.70359/bhc2000v025p016
  2. Liu, 1984, Comparative release of phenylpropanolamine HCl from long-acting appetite suppressant products: Acutrim vs, Dexatrim. Drug Develop. and Indus. Pharm., 10, 1639, 10.3109/03639048409039072 · doi:10.3109/03639048409039072
  3. Davis, 1979, Non-immunogenic polypeptides, 4, 337
  4. Ellory, 2010, AD Bangham (1922-2010), Physiology News, 79, 55
  5. Wu, 2020, Drug development through modification of small molecular drugs with Monodisperse poly(ethylene glycol)s, Org. Process. Res. Dev., 24, 1364, 10.1021/acs.oprd.0c00273 · doi:10.1021/acs.oprd.0c00273
  6. Lawrence, 1998, Development and comparison of iron dextran products, PDA J. Pharm. Sci. Technol., 52, 190
  7. Morrow, 2010, DNA drugs come of age, Sci. Am., 49
  8. Lindsley, 2011, The top prescription drugs of 2010 in the United States: antipsychotics show strong growth, ACS Chem. Neurosci., 2, 276, 10.1021/cn200050c · doi:10.1021/cn200050c
  9. Israeli, 1998, Paul Ehrlich's ingredients for success, Lancet, 352, 1712, 10.1016/S0140-6736(05)61497-3 · doi:10.1016/s0140-6736(05)61497-3
  10. FDA/CDER, 2000, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification, System
  11. Chaplin, 2020, Rybelsus: an oral formulation of the GLP-1 agonist semaglutide, Prescriber, 31, 32
  12. Li, 2019, Fabrication of gradient porous microneedle array by modified hot embossing for transdermal drug delivery, Mater. Sci. Eng. C, 96, 576, 10.1016/j.msec.2018.11.074 · doi:10.1016/j.msec.2018.11.074

Cited by

See all 475

Metadata

Authors
Park, H., Otte, A., & Park, K.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2022-02
Volume
342
Pages
53-65
ISSN
0168-3659 (ISSN-L)
OpenAlex
W4200575452
Cited by
475
References
121
FWCI
20.60
Type
journal article
Language
en
Open access
green
Funders
  • National Institute on Drug Abuse
  • Ralph W. and Grace M. Showalter Research Trust Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of drug delivery systems: From 1950 to 2020 and beyond. https://app.cochat.ai/papers/10.1016/j.jconrel.2021.12.030
The paper
Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2021.12.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.